Paushak Ltd
NSE: PAUSHAKLTD BSE: 532742Pharma
Paushak is India’s largest phosgene based specialty chemicals manufacturer serving pharmaceutical, agrochemical and performance industries. Paushak is part of the Alembic group of companies situated in Gujarat, India.. Alembic Ltd is the oldest pharmaceutical company in India founded in 1907. [1][2]
₹451
52W: ₹342 — ₹991
PE 28.3 · Book ₹199 · +127% vs bookMarket Cap₹1,112 Cr
Stock P/E28.3Price to Earnings
ROCE9.73%Return on Capital
ROE8.22%Return on Equity
Div. Yield0.55%Face Value ₹5
Weaknesses
- −The company has delivered a poor sales growth of 9.17% over past five years.
- −Company has a low return on equity of 10.0% over last 3 years.
- −Dividend payout has been low at 13.2% of profits over last 3 years
Shareholding Pattern
Promoters67.28%
FIIs0%
DIIs0.25%
Public32.48%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.97% | 66.97% | 66.97% | 67.14%▲0.2 | 67.14% | 67.28%▲0.1 | 67.28% | 67.28% |
| FIIs | 0% | 0% | 0% | 0.01%▲0.0 | 0%▼0.0 | 0% | 0% | 0% |
| DIIs | 0.29% | 0.34%▲0.1 | 0.39%▲0.0 | 0.53%▲0.1 | 0.53% | 0.7%▲0.2 | 0.67%▼0.0 | 0.25%▼0.4 |
| Public | 32.74% | 32.7%▼0.0 | 32.64%▼0.1 | 32.33%▼0.3 | 32.34%▲0.0 | 32.02%▼0.3 | 32.05%▲0.0 | 32.48%▲0.4 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 52 | 54 | 52 | 57 | 49 | 52 | 56 | 59 | 49 | 55 |
| Expenses | 33 | 35 | 40 | 40 | 35 | 36 | 38 | 44 | 37 | 38 |
| Operating Profit | 19 | 19 | 12 | 17 | 15 | 16 | 18 | 15 | 11 | 17 |
| OPM % | 36% | 35% | 23% | 30% | 30% | 30% | 32% | 25% | 23% | 30% |
| Net Profit | 14 | 18 | 10 | 14 | 15 | 10 | 12 | 9 | 6 | 13 |
| EPS ₹ | 5.54 | 7.42 | 4.19 | 5.77 | 6.2 | 3.9 | 4.89 | 3.5 | 2.5 | 5.07 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹219Cr, up 3.8% YoY. OPM at 28%.
Debt Position
Borrowings at ₹77Cr. Debt-to-equity ratio: 0.16x. Healthy balance sheet.
Capex Cycle
CWIP at ₹26Cr (7% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0.25% (+0.25pp change). FIIs: 0% (-0.02pp change). Promoters hold 67.28%.
Margin & Efficiency
ROCE declining from 32% (Mar 2015) to 10% (Mar 2026). Working capital days: 109.
Valuation
PE 28.3x with 9.73% ROCE. Price is 127% above book value of ₹199. Dividend yield: 0.55%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6 May - In accordance with Regulation 30 and Regulation 47 of SEBI Listing Regulations, newspaper advertisement related to Audited Financial Results for the quarter and financial year …
- Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026 5 May
- Board Meeting Outcome for Outcome Of Board Meeting 5 May - Board approved FY26 audited results; PAT Rs 39.33 crore, recommended Rs 2.50 dividend per share.
- Board Meeting Intimation for Board Meeting To Consider Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026 27 Apr - Board meets on 5 May 2026 to approve FY26 audited results and consider dividend.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Apr
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse